

Oxford Immunotec Global PLC
Form 8-K
April 01, 2016

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934**

Date of Report (date of earliest event reported): April 1, 2016

OXFORD IMMUNOTEC GLOBAL PLC

(Exact name of registrant as specified in its charter)

England and Wales

(State or other jurisdiction

of incorporation)

**001-36200 Not Applicable
(Commission (IRS Employer
File Number) Identification No.)**

94C Innovation Drive, Milton Park, Abingdon OX14 4RZ, United Kingdom

(Address of principal executive offices)

Registrant's telephone number including area code +44 (0) 1235 442780

Check appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01 Entry into a Material Definitive Agreement.

Effective April 1, 2016, Oxford Immunotec Ltd. (“OI Ltd.”), a wholly owned subsidiary of Oxford Immunotec Global PLC (the “Registrant”), entered into an Amendment to Marketing Authorization Holder Agreement (the “Amendment”) with Riken Genesis Co., Ltd.. (“Riken”). The Amendment amends the Marketing Authorization Holder Agreement between the parties dated July 29, 2011, as amended September 1, 2013 (the “Agreement”). The Agreement was originally filed as Exhibits 10.25 and 10.26 of our Registration Statement on Form S-1 (File No. 333-191737) on October 15, 2013. The Amendment establishes the applicable commission rates for Riken’s services beginning on the effective date of the Amendment.

The descriptions of the Agreement and the Amendment are summary in nature and are qualified in their entirety by reference to the full and complete terms of the Agreement and the Amendment, as applicable. The Registrant expects to file the Amendment as an exhibit to the Registrant’s quarterly report on Form 10-Q for the first quarter of 2016.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 1, 2016

OXFORD IMMUNOTEC GLOBAL PLC

By: /s/ Elizabeth M. Keiley
 Elizabeth M. Keiley
 VP and General Counsel